Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Evaluation of ATAD2 as a potential target in hepatocellular carcinoma

ABSTRACT: We evaluated differentially expressed genes (DEGs) between hepatocellular carcinoma cell lines (Hep3B, SNU449, and PLC/PRF/5) treated with ATAD2 siRNA or control using Affymetrix array data whether ATAD2 could be potential target in hepatocellular carcinoma.

ORGANISM(S): Homo sapiens

PROVIDER: GSE178243 | GEO | 2022/06/15

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Shared Molecules

Only show the datasets with similarity scores above: 0.5

Threshold

0.5

Similar Datasets

Proteome of Human hepatocellular carcinoma cell lines

Project description:The proteomic profiling of nine commonly used HCC cell lines Hep3B, HepG2, HepG2.2.15, HUH7, PLC/PRF/5, MHCC97L,MHCC97H,HCCLM3 and HCCLM6

2022-11-11 | PXD036643 | Pride

Evaluation of ATAD2 as a potential target in hepatocellular carcinoma

Project description:Evaluation of ATAD2 as a potential target in hepatocellular carcinoma

| PRJNA737831 | ENA

Project description:The role and mechanism of CSTF2 in hepatocellular carcinoma are unclear. We constructed CSTF2 knockout HUH7 and PLC/PRF/5 cells to analyze the function of CSTF2 in liver cancer and the downstream gene changes it induces.

2024-02-10 | GSE254649 | GEO

Expression data from CSC and Non-CSC of three HCC cell lines

Project description:Hepatocellular carcinoma (HCC) represents the major subtype of liver cancer, characterized with a high rate of recurrence and heterogeneity. Liver cancer stem cells (CSCs) may account for a hierarchical organization of heterogeneous cancer cells. However, how liver CSCs sustain their self-renewal remains largely unknown. We used microarrays to discover the long non-coding RNAs (lncRNAs) expression underlying cell stem cell (CSC) and non cell stem cell (non-CSC) and identified distinct lncRNAs during this process. We sorted CD13+CD133+ and CD13-CD133- cells from Hep3B, Huh7, and PLC/PRF/5 HCC cell lines as liver CSCs and non-CSCs, then hybridized on Affymetrix microarrays. We sought to identify distinct lncRNAs in liver CSCs.

2015-03-05 | E-GEOD-66529 | biostudies-arrayexpress

VARS1 overexpression in hepatocellular carcinoma cell lines

Project description:VARS1 was transiently overexpressed in Hep3B and SNU-387 hepatocellular carcinoma-derived cell lines.

2024-12-02 | PXD056392 | Pride

mRNA and RNC-mRNA deep sequencing of three hepatocellular carcinoma cell lines

Project description:We sequenced the total mRNA and translating mRNA (RNC-mRNA) of three hepatocellular carcinoma cell lines Hep3B, HCCLM3 and MHCC97H

2014-02-18 | GSE49994 | GEO

Transcription profiling of by array of human hepatocellular carcinoma cells with RNAi knockdown of Wilm's Tumor 1 gene expression

Project description:The Wilms' tumor 1 gene (WT1) encodes a transcription factor involved in cell growth and development. As we previously reported WT1 expression is hardly detectable in normal hepatic tissue but is induced in liver cirrhosis. Although WT1 has been found to be overexpressed in a number of malignancies, the role of WT1 in hepatocarcinogenesis has not been clarified. We found that WT1 is expressed in several human hepatocellular carcinoma (HCC) cell lines including PLC/PRF/5 and HepG2, and in HCC tumor tissue in 42% of patients. WT1 small interfering RNAs did not affect proliferation rate of HCC cells but abrogated their resistance to anoikis. Transcriptome analysis of PLC/PRF/5 cells after WT1 knockdown demonstrated upregulation of 251 genes and downregulation of 321. Ninety per cent of the former corresponded to metabolic genes mostly those characterizing the mature hepatocyte phenotype. On the contrary, genes that decreased upon WT1 inhibition were mainly related to defense against apoptosis, cell cycle and tumor progression. In agreement with these findings WT1 expression increased the resistance of liver tumor cells to doxorubicin, a compound used to treat HCC. Interestingly, doxorubicin strongly enhanced WT1 expression in both HCC cells and normal human hepatocytes. Among different chemotherapeutics, induction of WT1 transcription was restricted to topoisomerase 2 inhibitors. When WT1 expression was prohibited doxorubicin caused a marked increase in caspase-3 activation. In conclusion, WT1 is expressed in a substantial proportion of HCC contributing to tumor progression and resistance to chemotherapy, suggesting that WT1 may be an important target for HCC treatment.

2008-10-26 | E-GEOD-12886 | biostudies-arrayexpress

Combination treatment of sodium pentaborate pentahydrate, curcumin and piperine on hepatocellular carcinoma cells

Project description:The goal of this study is to determine the response of sodium pentaborate pentahydrate, curcumin and piperine and their combination on hepatocellular carcinoma cell lines, HepG2 and Hep3B

2023-06-30 | GSE207439 | GEO

MeRIP-seq analysis for CSTF2 knockout in HUH7 and PLC/PRF/5 cell lines

Project description:CSTF2 has been shown to have a certain oncogenic effect in hepatocellular carcinoma, but its mechanism remains unclear. Previous studies have suggested that CSTF2 can shorten the 3' untranslated region (3'UTR) of target genes. Considering that the 3'UTR contains numerous m6A modification sites, we hypothesize that CSTF2 may regulate mRNA m6A modification. We performed MeRIP-seq analysis to investigate the changes in m6A modification in CSTF2 knockout HUH7 and PLC/PRF/5 cell lines.

2024-05-30 | GSE268346 | GEO

The therapeutic potential and significance of the PELP1 signaling pathway in hepatocellular carcinoma

Project description:We examined the significance and therapeutic potential of targeting PELP1 in Hepatocellular carcinoma. Total RNA were isolated from HEP3B-control Sh, and HEP3B-PELP1-Sh cells using RNeasy mini kit, and total RNA was isolated for RNA-seq analysis. Our results demonstrated that PELP1 knockdown regulates pathways related to inflammation and interferon signaling and downregulates several pathways including MYC and E2F.

2024-10-16 | GSE254860 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data